GloGlo (YC) researcher Piotr Witkowski and Gary Meininger shared two different approaches to replacing the insulin-producing cells destroyed by type 1 diabetes.
Public source
Publisher name
Public post
screening a child for early signs of type 1 diabetes can reduce their chance of being dangerously sick at diagnosis from around 50% to around 3%. but almost nobody gets…
Company
GloGlo (YC)
Helping you stay in range: AI coaching and smarter energy gummies. Backed by Y Combinator.
- Industry
- Wellness and Fitness Services
- Company size
- 2–10 employees
About GloGlo (YC)
GloGlo is building a new consumer health brand for diabetics and the glucose-conscious. Our first products are the GloGlo AI glucose companion, which turns continuous glucose data into personalized insights and practical guidance, and GloGlo Energy Gummies, a fast, convenient, and enjoyable source of glucose for exercise, daily energy, and managing lows. We are starting with the Type 1 diabetes community, where glucose management is urgent and constant, before expanding to athletes and the broader metabolic health market. Our long-term vision is to make managing glucose and energy simpler, more intuitive, and more human. Backed by Y Combinator.
See moreLatest activity
Latest activity from GloGlo (YC)
8 signals
Research & Knowledge
GloGlo (YC) has spent the last few weeks running hundreds of AI agents on cell replacement research to cure type 1 diabetes.
Research & Knowledge
GloGlo (YC) researcher Piotr Witkowski and Gary Meininger shared that in another early study, a patient has continued producing insulin for 14 months without drugs that suppress the immune system.
Research & Knowledge
GloGlo (YC) researcher Anastasia Albanese-O'Neill shared that a clinic in San Diego screened around 2,000 children for autoantibodies that signal type 1 diabetes may be developing.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
PharmaSens AG
PharmaSens AG completed the data collection for its SMART02 clinical study evaluating the patch pump integrated with SiBionics Continuous Glucose Monitoring technology.
Research & Knowledge
Levels
Levels published research by Dr. Ziad Obermeyer and his collaborators on an AI model that identified a group at unusually high risk in ECG data, showing 85% of patients not considered high risk under existing clinical criteria.
Products & Services
Sansum Diabetes Research Institute
Sansum Diabetes Research Institute has built the infrastructure including an early-stage T1D clinic with a psychologist and stage-appropriate diabetes self-management education.
Research & Knowledge
Breakthrough T1D
Breakthrough T1D announced that the last day to submit LOIs for the Combined CGM-Pump RFA is September 2nd.
Research & Knowledge
International Diabetes Federation